IMS Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

IMS Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,715	Closed	-$227K	–	139
2024 Q4	$227K	Buy	1,715 +1	+0.1%	+$141	0.11%	127
2024 Q3	$250K	Buy	1,714 +2	+0.1%	+$289	0.11%	125
2024 Q2	$252K	Sell	1,712 -800	-32%	-$107K	0.12%	123
2024 Q1	$345K	Sell	2,512 -8	-0.3%	-$1.09K	0.16%	104
2023 Q4	$342K	Buy	2,520 +84	+3%	+$10.2K	0.17%	107
2023 Q3	$298K	Buy	+2,436	New	+$310K	0.18%	102
2022 Q1	–	Sell	-1,582	Closed	-$241K	–	145
2021 Q4	$241K	Hold	1,582	–	–	0.12%	125
2021 Q3	$256K	Buy	+1,582	New	+$266K	0.15%	117

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

IMS Capital Management's IBB Position: Q1 2025 in Review

IMS Capital Management sold out of iShares Biotechnology ETF (IBB) in Q1 2025, closing a stake of 1,715 shares — an estimated $227K sold.

IMS Capital Management first reported a position in IBB in Q3 2021 and held it in 8 quarters. The position peaked at $345K in Q1 2024. 832 funds tracked by Wall St. Rank hold IBB as of Q1 2025.

IMS Capital Management reported no remaining iShares Biotechnology ETF position as of Q1 2025 after selling out during the quarter.
IMS Capital Management sold 1,715 iShares Biotechnology ETF shares in Q1 2025, an estimated $227K.
IMS Capital Management first reported a position in iShares Biotechnology ETF in Q3 2021 and held it in 8 quarters.
IMS Capital Management's iShares Biotechnology ETF position peaked at $345K in Q1 2024.
832 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2025.

Based on IMS Capital Management's 13F filing for Q1 2025, filed 15 Jul 2025.